Thermo Fisher Q4 revenue $10.70B, adj EPS $6.54; full-year rev up 22% to $39.21B

THERMO FISHER SCIENTIFIC INC.

2021-FY EPS reported $19.46 revenue$39,211,000,000

Q4 GAAP diluted EPS $4.17 (vs $6.24); adjusted EPS $6.54 (vs $7.09); COVID-19 response rev $2.45B.
Full-year GAAP diluted EPS $19.46 (+22%); adjusted EPS $25.13 (+28%); COVID-19 response rev $9.23B.
Base business organic growth 8% in Q4, 14% for full year; acquisitions added 6% and 3%, respectively.
Invested $24B in 2021 strategic acquisitions (PPD, PeproTech); returned $2.4B to shareholders via buybacks and dividends.
2022 financial guidance to be provided during earnings call; no specific numbers in release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.